Evaluation of the diagnostic performance of different principles of SARS-CoV-2 commercial antibody tests in COVID-19 patients

Basit Öğe Kaydı
dc.contributor.authorDinç, Harika Öykü
dc.contributor.authorÖzdemir, Yusuf Emre
dc.contributor.authorAlkan, Sena
dc.contributor.authorDalar, Zeynep Güngördü
dc.contributor.authorGareayaghi, Nesrin
dc.contributor.authorSirekbasan, Serhat
dc.contributor.authorKocazeybek, Bekir
dc.contributor.authorTuyji Tok, Yeşim
dc.contributor.authorKuşkucu, Mert Ahmet
dc.contributor.authorKaraali, Rıdvan
dc.contributor.authorÖzbey, Doğukan
dc.contributor.authorAygün, Gökhan
dc.contributor.authorMidilli, Kenan
dc.date.accessioned2021-05-15T12:49:26Z
dc.date.available2021-05-15T12:49:26Z
dc.date.issued2021
dc.departmentTıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalıen_US
dc.description.abstractFollowing the emergence of severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) and using only PCR for diagnosis, antibody tests have been rapidly developed by various commercial companies. There are differences between the sensitivity and specificity of these tests due to the usage of different viral target proteins and antibody subclasses. In order to evaluate the diagnostic use of these tests, we aimed to examine the diagnostic performance, especially sensitivity and specificity, of SARS-CoV-2 IgM, IgA and IgG tests of various companies (Abbott, Roche, Euroimmun, Dia.Pro, Anshlabs, Vircell, UnScience and RedCell), which have different principles (ECLIA/CLIA, EIA, LFA). Current (n= 180) and past (n= 180) COVID-19 patients with clinical and molecular diagnosis of COVID-19 admitted to Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine Hospital, Pandemic Polyclinic with suspected COVID-19 infection, were included in our study. The patients admitted within the first 3 weeks after the onset of symptoms were included in the current patient group, and those admitted at the third and after the third week were included in the past patient group. Serum samples (n= 180) obtained from Istanbul Sisli Hamidiye Etfal Training and Research Hospital, Blood Center between April and June 2018 before the COVID-19 pandemic were included in the study as a control group. All the tests included in our study were studied with the recommendations of the manufacturer companies. Between the IgG detection tests with different principles in patients with past COVID-19, the sensitivity and specificity values of the most effective tests were; 86.7%/99.4% (Abbott), 86.1%/98.9% (Dia.Pro), 91.3%/95% (RedCell). Between the IgM detection tests with different principles in current COVID-19 patients, the sensitivity and specificity values were; 67.8%/99.4% (Abbott), 68.9%/98.6% (Vircell), 50%/97.5% (RedCell). Abbott IgM with a kappa coefficient of 0.67 and Vircell IgM + IgA test with a kappa coefficient of 0.65 showed the best fit in patients with current COVID-19 infection. In patients with past COVID-19, Abbott IgG with 0.86 kappa coefficient and Dia.Pro IgG test with 0.85 kappa coefficient showed the best match. Due to the low sensitivity of IgM detection antibody tests, they should not be preferred instead of real-time reverse transcriptase polymerase chain reaction in routine diagnosis. IgG detection tests may be preferred to detect the antibody response and the titers in people who have had COVID-19 for population seroprevalence and especially therapeutic immune plasma production. However, it is thought that the combined use of both ECLIA/CLIA-based and EIA/ELISA-based tests together may be more effective in routine use for SARS-CoV-2 IgG tests. © 2021 Ankara Microbiology Society. All rights reserved.en_US
dc.identifier.doi10.5578/mb.20219907
dc.identifier.endpage222en_US
dc.identifier.issn0374-9096
dc.identifier.issue2en_US
dc.identifier.pmid33882652
dc.identifier.scopus2-s2.0-85104693874
dc.identifier.scopusqualityQ3
dc.identifier.startpage207en_US
dc.identifier.trdizinid462725
dc.identifier.urihttps://doi.org/10.5578/mb.20219907
dc.identifier.urihttps://hdl.handle.net/20.500.12939/1012
dc.identifier.volume55en_US
dc.identifier.wosWOS:000642119100007
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.institutionauthorDalar, Zeynep Güngördü
dc.language.isotr
dc.publisherAnkara Microbiology Societyen_US
dc.relation.ispartofMikrobiyoloji Bulteni
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectIgAen_US
dc.subjectIgGen_US
dc.subjectIgMen_US
dc.subjectSARS-CoV-2en_US
dc.titleEvaluation of the diagnostic performance of different principles of SARS-CoV-2 commercial antibody tests in COVID-19 patients
dc.title.alternative[SARS-CoV-2 ile ilgili farkli prensipli ticari antikor testlerinin COVID-19 hastalarindaki tanisal performanslarinin de?erlendirilmesi]
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Evaluation of the diagnostic performance of different principles of SARS-CoV-2 commercial antibody tests in COVID-19 patients .pdf
Boyut:
413.35 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/ Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu